460 related articles for article (PubMed ID: 30354208)
1. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
2. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue.
Singh AB; Li H; Kan CF; Dong B; Nicolls MR; Liu J
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):8-16. PubMed ID: 24158514
[TBL] [Abstract][Full Text] [Related]
3. Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.
Dong B; Singh AB; Guo GL; Young M; Liu J
Int J Mol Med; 2019 May; 43(5):1927-1938. PubMed ID: 30896855
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
5. A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression.
Singh AB; Kan CF; Shende V; Dong B; Liu J
J Lipid Res; 2014 Jul; 55(7):1397-407. PubMed ID: 24792925
[TBL] [Abstract][Full Text] [Related]
6. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.
Papazyan R; Liu X; Liu J; Dong B; Plummer EM; Lewis RD; Roth JD; Young MA
J Lipid Res; 2018 Jun; 59(6):982-993. PubMed ID: 29559521
[TBL] [Abstract][Full Text] [Related]
7. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.
Jiang H; Zhang J; Du Y; Jia X; Yang F; Si S; Wang L; Hong B
Atherosclerosis; 2015 Dec; 243(2):523-32. PubMed ID: 26523989
[TBL] [Abstract][Full Text] [Related]
8. Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.
Dong B; Young M; Liu X; Singh AB; Liu J
J Lipid Res; 2017 Feb; 58(2):350-363. PubMed ID: 27940481
[TBL] [Abstract][Full Text] [Related]
9. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
12. Triciribine Engages ZFP36L1 and HuR to Stabilize LDLR mRNA.
Sundvold H
Molecules; 2020 Oct; 25(19):. PubMed ID: 33019656
[TBL] [Abstract][Full Text] [Related]
13. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
14. FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.
Singh AB; Dong B; Kraemer FB; Liu J
Physiol Rep; 2020 Mar; 8(5):e14387. PubMed ID: 32170842
[TBL] [Abstract][Full Text] [Related]
15. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
16. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
17. Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes.
Xu Y; Gao J; Gong Y; Chen M; Chen J; Zhao W; Tan S
Atherosclerosis; 2020 Mar; 297():111-119. PubMed ID: 32109664
[TBL] [Abstract][Full Text] [Related]
18. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
[TBL] [Abstract][Full Text] [Related]
19. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]